Skip to main content

18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!

European Journal of Nuclear Medicine and Molecular Imaging volume 47, pages 527–528 (2020)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Duarte PS. Letter to the Editor: 18F-NaF not cited in the EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2019:1–2. https://doi.org/10.1007/s00259-019-04556-5.

  2. Giovanella L, Treglia G, Iakovou I, Mihailovic J, Verburg FA, Luster M. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04458-6.

    Article  Google Scholar 

  3. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Based Med. 2016;21(4):125–7.

    Article  Google Scholar 

  4. Bassler D, Mueller KF, Briel M, Kleijnen J, Marusic A, Wager E, et al. Bias in dissemination of clinical research findings: structured OPEN framework of what, who and why, based on literature review and expert consensus. BMJ Open. 2016;6(1):e010024.

    Article  Google Scholar 

  5. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Waguespack SG; American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.

    Article  Google Scholar 

  6. Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, et al. Luster M; EANM and the EANM Thyroid Committee. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43(8):1486–90.

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. Clinic for Nuclear Medicine and Thyroid Competence Centre, Imaging Institute of Southern Switzerland, Via Ospedale 6, CH-6500, Bellinzona, Switzerland

    Giorgio Treglia & Luca Giovanella

  2. Division of Nuclear Medicine and Molecular Imaging, CHUV and University of Lausanne, Lausanne, Switzerland

    Giorgio Treglia

  3. Clinic for Nuclear Medicine, University Hospital and University of Zürich, Zürich, Switzerland

    Luca Giovanella

Authors
  1. Giorgio Treglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Giovanella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Giovanella.

Ethics declarations

Conflict of interest

L.G. is member of Roche Diagnostics advisory board and received research grants and speaker fees from Roche Diagnostics, IBSA and Sanofi-Genzyme. G.T. declares that he has no conflict of interest. JM declares that she has no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Oncology–Head and Neck.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Treglia, G., Giovanella, L. 18F-Fluoride (18F-NaF) PET/CT in medullary thyroid carcinoma: far from evidence, far from guidelines!. Eur J Nucl Med Mol Imaging 47, 527–528 (2020). https://doi.org/10.1007/s00259-019-04563-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-019-04563-6